WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014181085) TUMOUR THERAPY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/181085    International Application No.:    PCT/GB2014/051329
Publication Date: 13.11.2014 International Filing Date: 30.04.2014
IPC:
A61K 47/48 (2006.01), A61K 45/06 (2006.01)
Applicants: BAGSHAWE, Kenneth Dawson [GB/GB]; (GB)
Inventors: BAGSHAWE, Kenneth Dawson; (GB)
Agent: GALLAFENTS LLP; 1 Sans Walk London EC1R 0LT (GB)
Priority Data:
1308363.9 09.05.2013 GB
Title (EN) TUMOUR THERAPY
(FR) THÉRAPIE ANTITUMORALE
Abstract: front page image
(EN)There is disclosed a therapeutic system comprising: (i) a prodrug; (ii) an enzyme that has an active site which is capable of converting the prodrug into a drug; (iii) a vascular-targeting agent; and (iv) an inhibitor which, following administration, reduces the level of enzyme activity. There is also disclosed a therapeutic system for the treatment of cancer employing the four components (i) - (iv) in which the four components are combined into two groups of components. The two groups of components may be formulated or modified such that one component is metabolically active before the other.
(FR)La présente invention concerne un système thérapeutique comprenant : (i) un promédicament ; (ii) une enzyme qui comporte un site actif capable de convertir le promédicament en un médicament ; (iii) un agent de ciblage vasculaire ; et (iv) un inhibiteur qui, après administration, diminue le niveau d'activité enzymatique. La présente invention concerne également un système thérapeutique destiné au traitement du cancer employant les quatre composants (i) - (iv) dans lequel les quatre composants sont combinés en deux groupes de composants. Les deux groupes de composants peuvent être formulés ou modifiés de sorte que l'un des composants soit métaboliquement actif avant l'autre.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)